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Abstract: A considerable body of evidence suggests the involvement of serotonin neurotransmission in the pathogenesis 
of panic disorder. Research on pathways and functions of tryptophan, an essential amino acid converted into serotonin, may 
advance our understanding of serotonergic actions in panic disorder and related phenomena. The investigative approaches 
in this ﬁ  eld include manipulations of tryptophan availability as well as genetic association and functional brain imaging 
studies. In this review we examine the principle ﬁ  ndings of these studies and propose further research directions.
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Panic disorder (PD) is a prevalent and serious illness in need of a better understanding of its neurobio-
logical basis to improve treatment outcomes. The pathogenesis, clinical manifestations and treatment 
effects of PD are thought to be substantially related to the functions of serotonin or 5-hydroxytryptamine 
(5-HT) neurotransmission. The crucial role of 5-HT in PD has been suggested by clinical studies dem-
onstrating that medications speciﬁ  cally increasing the synaptic availability of 5-HT, especially the 
selective 5-HT re-uptake inhibitors (SSRIs), are particularly effective in the treatment of PD (Nutt, 
1998). Extensive experience with SSRIs in the treatment of PD and the effect of tryptophan depletion 
(TD) to undermine this action underscored the necessity of increased synaptic availability of 5-HT for 
achieving remission. Furthermore, growing data from experimental and neuroimaging studies have 
suggested that altered availability of brain 5-HT is associated with PD; however the exact mechanisms 
of a possible disturbance in 5-HT metabolism are not fully understood (Maron and Shlik, 2006). 5-HT 
is synthesized from the essential amino acid tryptophan via intermediate metabolite, 5-hydroxytrypto-
phan (5-HTP), and stored in reserpine-sensitive vesicles until released into the synaptic cleft by nerve 
impulses. The conversion of tryptophan into 5-HTP is regulated by tryptophan hydroxylase (TPH), the 
rate limiting enzyme in biosynthesis of 5-HT. In the next step, 5-HTP is decarboxylated by aromatic 
acid decarboxylase to 5-HT. Unlike 5-HTP, tryptophan can be shunted into kynurenine via tryptophan 
2,3-dioxygenase, making tryptophan unavailable for 5-HT production (Birdsall, 1998; Ruddick et al. 
2006). TPH can be inhibited by numerous factors, including stress, insulin resistance, vitamin B6 deﬁ  -
ciency, and insufﬁ  cient magnesium, that may increase the conversion of tryptophan to kynurenine. 
Under normal conditions, the enzyme TPH is only about 50% saturated in brain, therefore the synthesis 
of 5-HT is dependent on the availability of free plasma tryptophan, whereas alterations in its availability 
correlate with the amount of synthesized 5-HT (Schaechter and Wurtman, 1990). Presently, the central 
5-HT pathways remain the main targets in the research on the neurobiology of PD. In this paper we 
review the studies focusing on the role of tryptophan and discuss research directions in this area.
Experimental Studies
Deakin and Graeff (1991) have proposed that in certain brain regions 5-HT restrains panic behaviour 
and therefore 5-HT deﬁ  cit may predispose to panic reactions. Two complementary approaches in altering 
the tryptophan availability were found helpful to understand the role of 5-HT in the pathophysiology 4
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of PD. First is the acute tryptophan depletion (ATD) 
achieved by a dietary manipulation leading to a 
rapid reduction in plasma tryptophan levels, typi-
cally 70%–80% reduction within 5 hours (Young 
et al. 1985). The drop in the peripheral source of 
5-HT is reﬂ  ected by a substantial decrease in the 
brain 5-HT levels. For instance, the rate of 5-HT 
synthesis in vivo using positron emission tomog-
raphy (PET) was reduced up to 40% of baseline 
values after ATD in healthy subjects (Nishizawa 
et al. 1997). The methods and psychopharmaco-
logical rationale of ATD as well as its application 
in psychiatric research have been recently reviewed 
in detail (Hood et al. 2005; Bell et al. 2005). An 
opposite effect of tryptophan supplementation 
could be achieved with the use of 5-HT precursors, 
particularly 5-HTP, which increases brain concen-
trations of 5-HT (den Boer and Westenberg, 1990; 
van Vliet et al. 1996). Both methods could be more 
salient under conditions of experimental challenge 
with panicogenic agents, such as carbon dioxide 
(CO2), cholecystokinin-tetrapeptide (CCK-4), a 
CCK brain subtype receptor agonist, or benzodiaz-
epine receptor antagonist, ﬂ  umazenil. The main 
results from the studies investigating the effects of 
5-HT synthesis rate manipulation on panic 
responses are summarized in Table 1.
Depletion studies
ATD alone is not anxio- or panicogenic in unmed-
icated PD patients or healthy subjects (Goddard 
et al. 1994, 1995; Klaassen et al. 1998) but may 
increase the susceptibility to panic under challenge 
conditions. ATD was associated with an increased 
respiration and subjective breathlessness in patients 
with PD as compared to controls in response to 5% 
CO2 challenge, but no signiﬁ  cant between-group 
differences were observed on primary measures of 
panic or anxiety (Kent et al. 1996). Klaassen et al. 
(1998) have shown that in healthy subjects ATD 
signiﬁ  cantly increased 35% CO2-induced somatic, 
but not cognitive, panic symptoms in male subjects 
with a similar panic rate in ATD and placebo 
groups. Koszycki et al. (1996) have found that ATD 
did not inﬂ  uence the panicogenic effect of CCK-4 
in healthy males, although it did augment 
CCK-4-mediated neuroendocrine activation. Fur-
ther studies have mostly proven that ATD increases 
the sensitivity to CO2 challenge in patients with 
PD. Speciﬁ  cally, Miller et al. (2000) showed that 
ATD caused a greater panic and anxiogenic 
response and a higher rate of panic attacks after 
5% CO2 inhalation in PD patients, but not in 
healthy subjects. Another study in patients with 
PD by Schruers et al. (2000) demonstrated a sig-
niﬁ  cant increase in anxiety and panic symptoms 
induced by 35% CO2 inhalation in the ATD group 
when compared to the placebo condition. Recently, 
Hood et al. (2006) assessed the effects of ATD on 
neuroendocrine, autonomic and psychological 
responses to single breath 35% CO2 inhalation in 
healthy volunteers. They observed no exacerbation 
of the provoked anxiety symptoms and no increase 
in the psychological response to a challenge 
stressor.
A study by Bristol group found that ATD 
reversed the antipanic effect of chronic treatment 
with the SSRI paroxetine in PD patients, mani-
fested as an increase in panicogenic response to a 
challenge with ﬂ  umazenil (Bell et al. 2002). This 
ﬁ  nding supported the hypothesis that a decrease in 
5-HT neurotransmission predisposes to panic 
attacks and that the antipanic effect of SSRIs 
depends upon the availability of 5-HT in the brain 
(Nutt et al. 1999). Later, the same group demon-
strated that ATD also counteracted the therapeutic 
effect of SSRIs in patients with social anxiety 
disorder (SAD). Particularly, they found that ATD 
induced a signiﬁ  cant increase in anxiety when 
listening to an anxiogenic autobiographical script, 
supporting the idea that 5-HT is important in 
maintaining the response to SSRIs in SAD 
(Argyropoulos et al. 2004). In the next study they 
aimed to characterize the effect of ATD on 
cardiovascular and psychological responses to 
stress challenge in recovered patients with PD or 
SAD (Davies et al. 2006). The results showed that 
both systolic and diastolic blood pressure responses 
to stress were signiﬁ  cantly greater under ATD than 
control condition, as were the psychological or 
anxiety responses to stress, suggesting that 5-HT 
is involved in the control of both cardiovascular 
and psychological aspects of acute stress response. 
The lack of correlation between blood pressure and 
psychological responses to stress in this study 
indicated that 5-HT may affect cardiovascular and 
psychological domains independently rather than 
the cardiovascular responses being secondary to 
psychological changes.
Recently, Tartu-Bristol collaborative study has 
extended this line of research by evaluating the 
effect of ATD on CCK-4-induced symptoms in 
patients with PD who had responded to the 5
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treatment with a SSRI citalopram (Tõru et al. 
2006). The results of this study showed that ATD 
did not affect behavioural or cardiovascular 
response to a CCK-4 challenge in the responders 
after 10-week treatment with citalopram, demon-
strating that an acute decline in the central avail-
ability of 5-HT does not reverse the protective 
effect of SSRI treatment on CCK-4-induced panic. 
This ﬁ  nding suggested that the reduced sensitivity 
to CCK-4 after SSRI treatment may be due to 
mechanisms other than an increase in 5-HT avail-
ability in the brain, and that the panicogenic effects 
of CCK-4 and ﬂ  umazenil may be modulated dif-
ferently by 5-HT. Interestingly, the studies examin-
ing effects of ATD in obsessive-compulsive 
disorder (OCD) in patients remitted on SSRI, either 
on medication or drug-free, failed to show any 
signiﬁ  cant exacerbation in OCD or related symp-
toms under ATD condition at rest (Barr et al. 1994; 
Smeraldi et al. 1996; Huwig-Poppe et al. 1999; 
Külz et al. 2007) or during symptom provocation 
(Berney et al. 2006). The lack of effect of ATD on 
OCD symptoms suggests that the durability of the 
effects of SSRI in OCD may be less dependent on 
the synaptic availability of 5-HT.
Supplementation studies
Early studies with direct administration of 
tryptophan did not demonstrate any differences in 
the reactivity between patients with PD and healthy 
subjects. Speciﬁ  cally, Charney et al. (1982) showed 
that intravenous infusion of L-tryptophan was not 
accompanied by anxiety symptoms, although 
it induced significant increases in prolactin 
and growth hormone in healthy subjects as com-
pared to placebo injection. Later they also estab-
lished that the ability of tryptophan to increase 
prolactin levels was not different between the PD 
patients and healthy subjects and was not inﬂ  u-
enced by alprazolam treatment (Charney and 
Heninger, 1986). Notably, a clinical observation 
was made that oral tryptophan augmentation did 
not potentiate the beneﬁ  cial effect of 10-week 
treatment with clomipramine on phobic avoidance, 
phobic fears or the incidence of panic attacks in a 
small sample of patients with agoraphobia or social 
phobia (Pecknold et al. 1982).
Studies with 5-HTP have shown that administration 
of this immediate precursor of 5-HT had beneﬁ  cial 
effects on panic attacks in patients with anxiety 
disorders (Kahn and Westenberg, 1985; Kahn et al. 
1987). Also it was reported that an acute adminis-
tration of 60 mg of 5-HTP was not anxiogenic in 
healthy subjects and was felt as a relief in patients 
with PD, whereas 5-HTP infusion led to substan-
tial, but similar increases in plasma cortisol, beta-
endorphin and melatonin levels in both groups (den 
Boer and Westenberg, 1990). Later, van Vliet et al. 
(1996) assessed the psychological and hormonal 
effects of 5-HTP in small samples of PD patients 
and healthy controls who received an i.v. challenge 
with 10, 20 and 40 mg of 5-HTP and placebo in 
random order on four different occasions. No panic 
or anxiety symptoms were observed in any of the 
groups during and after infusion of placebo or dif-
ferent doses of 5-HTP. Only infusion with 40 mg 
5-HTP led to an increase in plasma cortisol in both 
patients and controls, whereas rise in plasma cor-
tisol level was higher in PD patients only 30 min 
after infusion. Conversely, Schruers et al. (2002b) 
have found that the administration of 200 mg 
5-HTP restrained panic responses to 35% CO2 
challenge in patients with PD, but not in healthy 
subjects. Furthermore they detected a signiﬁ  cant 
rise in salivary cortisol levels in both patients and 
controls following acute administration of 5-HTP, 
whereas no such effects were seen after placebo 
(Schruers et al. 2002a). Our study in healthy 
volunteers has shown that 200 mg of 5-HTP 
signiﬁ  cantly lowered the panic rate and intensity 
of cognitive symptoms of panic in females and the 
intensity of somatic symptoms of panic in males 
(Maron et al. 2004b). These ﬁ  ndings suggested 
that an increased availability of 5-HT may 
have a gender-dependent protective effect in 
CCK-4-induced panic. We also observed a 
signiﬁ  cantly greater increase in blood pressure 
after CCK-4 injection in 5-HTP-group in comparison 
to placebo with a similar trend in heart rate. 
Although it is known that 5-HT has vasotonic 
properties, the mechanism of these paradoxi-
cal cardiovascular effects of 5-HTP during 
CCK-4-induced panic is not clear.
In summary, most of the above-mentioned stud-
ies demonstrate that a decrease in 5-HT synaptic 
availability by ATD increases susceptibility to 
panic and, conversely, an increase in 5-HT neuro-
transmission particularly by administration of 
5-HTP has antipanic effects. The lack of such 
effects with L-tryptophan could probably be 
explained by competing pathways of the synthesis 
of 5-HT and kynurenine. Notably, the use of higher 
doses of 5-HTP demonstrated more prominent 8
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anti-panic effects. Although it is quite clear that 
acute pre-treatment with 5-HTP increases the net 
amount of released 5-HT and its synaptic avail-
ability (Dreshﬁ  eld-Ahmad et al. 2000; Fickbohm 
and Katz, 2000), the possible antipanic action mode 
of 5-HTP requires further scrutiny. The increase in 
plasma cortisol and prolactin following 5-HTP 
administration is modulated by different postsyn-
aptic receptors, including 5-HT1A, 5-HT2A, 
5-HT2C, and 5-HT3 (Meltzer and Maes, 1994; 
Meltzer et al. 1997). Pre-treatment with pindolol, 
a 5-HT1A partial antagonist, signiﬁ  cantly inhibited 
the prolactin, but not the cortisol response to 5-HTP 
(Meltzer and Maes, 1994), whereas ritanserin, a 
5-HT2A/5-HT2C antagonist, did not block the 
prolactin response to tryptophan (Deakin, 1996) 
and even increased it in another study (Charig et al. 
1986). It is not known whether neuroendocrine and 
antipanic effects of 5-HTP are mediated via the 
same 5-HT receptors. Therefore, further experi-
mental studies with selective 5-HT-ergic antago-
nists are needed to clarify the antipanic action of 
5-HTP and its clinical relevance. A fundamental 
question to be addressed in further studies is 
whether the supposed 5-HT deﬁ  cit is a primary 
factor in the manifestations of PD or 5-HT enhance-
ment exerts a protective inﬂ  uence through projec-
tions on other neurotransmission systems, which 
are responsible for triggering panic attacks.
Genetic Studies
There have been increasing efforts to determine 
genes in 5-HT system related to vulnerability to 
PD. TPH gene has emerged as a major candidate 
for genetic association studies in many psychiatric 
disorders, including PD. Recently, the two genes 
coding TPH have been differentiated as TPH1 and 
TPH2 (Walther et al. 2003). The association studies 
with TPH1 gene have shown lack of association 
between its polymorphisms, such as 1095T/C, 
218A/C or 779A/C and PD (Fehr et al. 2001; Han 
et al. 1999; Maron et al. 2005a, b). Zill et al. 
(2004b) have established that human TPH1 and 
TPH2 are expressed in nearly equal amounts in 
several brain regions such as the frontal cortex, 
thalamus, hippocampus, hypothalamus and 
amygdala, while TPH2 is predominant in the brain 
stem, the major locus of the 5-HT-producing 
neurons, and TPH1 mRNA is exclusively present 
in peripheral tissues. A number of studies have now 
indicated the associations between several TPH2 
polymorphisms and various psychiatric disorders 
(Zhang et al. 2004). Possible associations were 
found between various TPH2 polymorphisms and 
major depression (Zill et al. 2004a; Zhang et al. 
2005; Zhou et al. 2005), response to antidepres-
sants (Peters et al. 2004), suicidal behaviour (Zill 
et al. 2004c; Zhou et al. 2005), ADHD (Sheehan 
et al. 2005; Walitza et al. 2005), autism (Coon et al. 
2005), bipolar disorder (Harvey et al. 2004) and 
OCD (Mössner et al. 2006b). In contrast, other 
studies failed to ﬁ  nd associations between TPH2 
polymorphisms and suicidality or mood disorders 
(De Luca et al. 2004, 2005; Garriock et al. 2005). 
Despite the fact that TPH2 appears to be principally 
responsible for the synthesis of 5-HT in the brain 
(Zhang et al. 2004), the functional meaning of 
TPH2 polymorphisms as well as their regulatory 
effect on the 5-HT synthesis rate remain unclear 
(Breidenthal et al. 2004).
Presumably, TPH2 rather than TPH1 gene poly-
morphisms are more relevant targets in PD due to 
a stronger relevance of TPH2 to the regulation of 
5-HT neurotransmission. To test this hypothesis 
we compared the distributions of TPH2 gene poly-
morphisms in the samples of Estonian patients with 
PD (n = 213) and matched healthy subjects 
(n = 303) (Maron et al. 2007). Two polymorphic 
loci from the TPH2 gene were included in our 
study: rs1386494, previously associated with major 
depression by Zill et al. (2004a) and rs1386483, 
recently associated with impulsivity (Stoltenberg 
et al. 2006). Overall we found no signiﬁ  cant asso-
ciations between these SNPs and PD. These 
findings were similar to the results of the by 
Mössner et al. (2006a), where no associations were 
seen between PD and two other common SNPs, 
rs4570625 and rs4565946, located respectively in 
the putative transcriptional control region and in 
the intron 2 of TPH2. Thus, data so far seem to 
disprove the hypothesis of a link between genetic 
variations in the TPH2 gene and susceptibility to 
PD. Nevertheless, our separate analyses by gender 
revealed a positive association with rs1386494 
SNP in females with pure PD phenotype (n = 52), 
but not in the total female group (n = 163) or in the 
subgroup of females with PD and affective comor-
bidity, including major depression (n = 111). 
Particularly, we detected that G/G genotype and 
G allele were less frequent in females with pure 
PD as compared to control females (p = 0.01 and 
p = 0.02, respectively), indicating a possible 
gender-speciﬁ  c effect of rs1386494 variants in pure 9
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phenotype of PD (Maron et al. 2007) In order to 
further clarify the involvement of this SNP in PD, 
we recently examined its effect on the vulnerability 
to CCK-4-induced panic attacks in 47 male and 
63 female healthy subjects (Tõru et al. unpub-
lished). We detected significant associations 
between rs1386494 and the rate of panic attacks 
induced by CCK-4 injection. Particularly, both 
G/G genotype and G allele were more frequent in 
panickers as compared to non-panickers (p = 0.03 
and p = 0.009, respectively). Further analyses 
showed that these associations remained signiﬁ  cant 
only in female subjects. Thus, the challenge test 
confirmed the involvement of TPH2 genetic 
polymorphism, rs1386494, in panicogenesis and 
particularly in susceptibility to panic attacks. How-
ever, the opposite direction of association between 
the patients and healthy subjects complicates the 
interpretation of these ﬁ  ndings.
Brain Imaging Studies
The visualization of neurochemical processes has 
provided more evidence for the involvement of 
5-HT-ergic pathways in panic circuitry. Using the 
SPECT tracer [
123I]nor-β-CIT we demonstrated 
that symptomatic patients with PD had signiﬁ  -
cantly lower 5-HT transporter (5-HTT) binding in 
the midbrain raphe, in the temporal lobes, and in 
the thalamus than the healthy controls. The patients 
with PD in remission had normal 5-HTT-binding 
properties in the midbrain and in the temporal 
regions, but still a signiﬁ  cantly lower thalamic 
5-HTT binding (Maron et al. 2004a). Furthermore, 
two positron emission tomography (PET) studies 
have revealed a marked reduction of 5-HT1A 
receptor binding in many brain regions in PD using 
the tracer WAY100635. Particularly, PD patients 
showed signiﬁ  cantly decreased 5-HT1A receptor 
binding in the anterior and posterior cingulate 
cortices, and in the midbrain raphe in comparison 
to healthy controls without any between-group 
differences in the anterior insula, the mesiotemporal 
cortex, and the anterior temporal cortex (Neumeister 
et al. 2004). Another PET study has demonstrated 
a reduced binding to 5-HT1A receptors in the raphe 
region as well as in the amygdala, and the orbito-
frontal and temporal cortices in untreated patients 
with PD (Nash et al. in press). PD patients who 
fully recovered after treatment with SSRIs in this 
study showed normalized density of postsynaptic 
receptors, but there remained a reduction in the 
density of 5-HT1A receptors in the raphe and in 
the hippocampus, suggesting a trait nature of these 
alterations. However no signiﬁ  cant difference was 
seen in global postsynaptic binding for treated 
patients versus controls. Based on these data 
and the hypothesis of 5-HT deﬁ  cit in PD, we 
suggested that such alterations in central 5-HT 
system in PD could reﬂ  ect a compensatory process 
attempting to increase 5-HT neurotransmission to 
inhibit the panic (Maron and Shlik, 2006).
To prove this assumption a measurement of 
5-HT synthesis rate in the brain of patients with 
PD would be warranted. Of interest, a decreased 
index of 5-HT synthesis, as measured by PET with 
α-[11C]methyl-l-tryptophan trapping, was detected 
in parts of the limbic and paralimbic cortices of 
patients with major depression (Rosa-Neto et al. 
2004). Another PET study demonstrated a 
signiﬁ  cant increase in 5-HT synthesis rate in the 
prefrontal cortex of patients with depression who 
had received treatment with SSRI citalopram alone 
or with pindolol (Berney et al. 2008). Considering 
that major depression is the most often comorbid 
condition in patients with PD, and that principal 
therapeutic mechanism of SSRIs could be similar 
for both conditions, further PET studies of 5-HT 
synthesis rate in PD should be of interest.
Conclusive Remarks
Tryptophan-related research has significantly 
extended our knowledge on the role of 5-HT in 
PD. Although a number of studies manipulating 
tryptophan availability provide reasonable evidence 
for a protective inﬂ  uence of 5-HT against panic 
responses, some of the ﬁ  ndings are divisive, indi-
cating that the role of 5-HT in PD is not unique 
and 5-HT may interact differently with relevant 
neurotransmitter systems. Recent genetic studies 
tentatively point to the function of TPH2 gene in 
a predisposition to panic, but these data need to be 
replicated and extended. The functional role of 
TPH2 genetic polymorphisms on tryptophan 
metabolism requires further elucidation. The char-
acterisation of molecular mechanisms underlying 
tryptophan metabolism in different neuronal 
populations might lead to novel therapeutic strate-
gies based on specific regulation of different 
metabolic pathways for tryptophan (Ruddick et al. 
2006). Such studies may also shed more light on 
the relatioships between pathways of tryptophan 
metabolism and features of PD in it’s different 10
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clinical stages. The gender difference in the role 
of 5-HT in panic attacks as suggested by some 
experimental and genetic studies deserves a special 
attention. Pertinently, the prevalence of PD is more 
than twice higher in females than in males (Eaton 
et al. 1994) and synthesis rate of 5-HT is lower in 
healthy females than in males throughout the cere-
bral cortex (Nishizawa et al. 1997; Sakai et al. 
2006). Furthermore, ATD signiﬁ  cantly impaired 
the recognition of fearful facial expressions in 
female, but not in male healthy volunteers (Harmer 
et al. 2003). These ﬁ  ndings substantiate the tryp-
tophan-serotonin connection in PD and call for 
more attention to the vulnerability of 5-HT system 
in females in the further research on PD and related 
behaviours.
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